

1 **An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results**  
2 **of an interim analysis of a phase III, parallel group, randomized, double-**  
3 **blind, active-controlled study**

4 Julio Torales<sup>a</sup>, Osmar Cuenca-Torres<sup>a</sup>, Laurentino Barrios<sup>a</sup>, Luis Armoa- Garcia<sup>a</sup>, Gladys  
5 Estigarribia<sup>a</sup>, Gabriela Sanabria<sup>a</sup>, Meei-Yun Lin<sup>b</sup>, Josue Antonio Estrada<sup>b</sup>, Lila Estephan<sup>b</sup>, Hao-  
6 Yuan Cheng<sup>b</sup>, Charles Chen<sup>b</sup>, Robert Janssen<sup>c</sup>, Chia-En Lien<sup>b,d\*</sup>

7

8 <sup>a</sup>School of Medical Sciences, National University of Asunción, San Lorenzo, Paraguay

9 <sup>b</sup>Medigen Vaccine Biologics Corporation, Taipei, Taiwan

10 <sup>c</sup>Dynavax Technologies Corporation, Emeryville, CA, USA

11 <sup>d</sup>Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei, Taiwan

12

13 \*Corresponding author : Chia-En Lien, MD, DrPH. email: allenlien@medigenvac.com

14 Tel.: +886-2-7745-0830, Address: 7F., No. 16, Ln. 120, Sec.1, Neihu Rd., Taipei City 114, Taiwan.

15

## 1 **Abstract**

2 **Background:** Data from previous studies of the MVC-COV1901 vaccine, a subunit vaccine  
3 against SARS-CoV-2 based on the stable prefusion spike protein (S-2P) adjuvanted with CpG  
4 1018 adjuvant and aluminum hydroxide, suggest that the vaccine is generally safe and elicits a  
5 good immune response in healthy adults and adolescents. By comparing with AZD1222, this  
6 study adds to the findings from previous trials and further evaluates the breadth of protection  
7 offered by MVC-COV1901.

8 **Methods :** In this phase 3, parallel group, randomized, double-blind, active-controlled trial  
9 conducted in 2 sites in Paraguay, we assigned adults aged 18 to 91 years in a 1:1 ratio to receive  
10 intramuscular doses of MVC-COV1901 or AZD1222 administered as scheduled in the clinical  
11 trial. Serum samples were collected on the day of vaccination and 14 days after the second dose.  
12 Primary and secondary safety and immunogenicity endpoints were assessed. In addition, other  
13 outcomes investigated were cross-reactive immunity against the Omicron strain and the  
14 induction of IgG subclasses.

15 **Results :** A total of 1,030 participants underwent randomization. Safety data was derived from  
16 this set while primary immunogenicity data involved a per-protocol immunogenicity (PPI) subset  
17 including 225 participants. Among the participants, 58% are seropositive at baseline. When  
18 compared against AZD1222, MVC-COV1901 exhibited superiority in terms of neutralizing  
19 antibody titers and non-inferiority in terms of seroconversion rates. Reactogenicity was generally  
20 mild and no serious adverse event was attributable to MVC-COV1901. Both vaccines have a  
21 Th1-biased response predominated by the production of IgG1 and IgG3 subclasses. Omicron-

22 neutralizing titers were 44.5 times lower compared to wildtype-neutralizing titers among  
23 seronegative individuals at baseline. This fold-reduction was 3.0 times among the seropositive.

24 **Conclusion:** Results presented here demonstrate the safe and robust immunogenicity from  
25 MVC-COV1901. Previous infection coupled with vaccination of this vaccine may offer  
26 protection against the Omicron strain though its durability is still unknown.

27 **Keywords:** COVID-19; SARS-CoV-2 vaccine; MVC-COV1901; phase 3 trial; Omicron strain;  
28 subunit vaccine

29 **ClinicalTrials.gov registration:** NCT05011526

## 1 **Introduction**

2           Since it was first reported in December 2019, COVID-19 has rapidly spread affecting  
3 millions of lives and causing over 6 million deaths worldwide [1]. High transmission rates have  
4 threatened and quickly overwhelmed health systems. The urgency of addressing this pandemic  
5 has led to the accelerated development of vaccines from various platforms. To date, over 63.4%  
6 of the world's population has received at least one dose of a COVID-19 vaccine but the  
7 inequitable distribution of vaccine remains a problem. It is estimated that only 13.6% of people  
8 in low-income countries have received at least one dose of an approved COVID-19 vaccine [1].  
9 Further increasing vaccine coverage and improving vaccine equity require surpassing logistical  
10 and supply constraints and the use of vaccines that are proven safe and effective and offer  
11 breadth in terms of protection

12           During late 2020, reports from different countries confirmed the emergence of SARS-  
13 CoV-2 variants that caused differing degrees of transmission, ability to cause severe disease and  
14 immune evasion [2]. In November 2021, the first case of the Omicron variant was reported in  
15 South Africa [3]. Although found to have a lesser risk for severe disease than the previously  
16 discovered Delta variant, mutations in the Omicron equipped the variant with greater  
17 transmissibility, effectivity in avoiding the human immune response and resistance against some  
18 existing treatments [4,5]. By the end of March 2022, more than 90% of SARS-CoV-2 infections  
19 worldwide were caused by this variant [1]. For populations receiving insufficient protection, an  
20 epidemic of the virus may lead to detrimental effects. Although the incidence of severe disease is  
21 lower, higher transmission leading to a large volume of cases, could overwhelm health systems  
22 and threaten economies. As aforementioned, it is crucial that we find solutions that are safe and  
23 effective and offer protection against the different variants of the virus.

24 MVC-COV1901 is a subunit vaccine based on the stable prefusion spike protein (S-2P)  
25 of SARS-Cov-2 adjuvanted with CpG 1018 adjuvant and aluminum hydroxide and has been  
26 approved for use in 3 countries [6,7]. A large phase 2 clinical trial has demonstrated its favorable  
27 safety and immunogenicity profiles [8]. An immunobridging assessment demonstrated non-  
28 inferiority in terms of immunogenicity to AZD1222 with a geometric mean titer (GMT) of  
29 neutralizing antibodies equivalent to 3.8 times that of AZD1222. [9]. In terms of safety, the V-  
30 Watch program, launched by the Taiwan Centers for Disease Control to monitor post-marketing  
31 safety, reported no serious adverse effects for MVC in 2 million doses administered [10]. Among  
32 adolescents, the vaccine was well tolerated and had an immunogenic effect that is non-inferior to  
33 that of young adults [11]. For stability, this vaccine can be transported and stored in standard  
34 refrigeration temperatures and can, therefore, be easily utilized in low-resource settings [12].  
35 Here, we report an interim analysis of a phase 3 trial to assess the safety, tolerability, and  
36 immunogenicity of two doses of the MVC-COV1901 compared with AZD1222. We assessed  
37 the superiority of MVC-COV1901 against AZD1222 in terms of neutralizing antibodies and its  
38 non-inferiority in terms of seroconversion. We also looked at other dimensions of immunity  
39 particularly the profile of IgG subclass antibody responses among vaccinated individuals. As a  
40 huge majority of the infections globally are caused by the Omicron variant, it is imperative that  
41 we investigate the immunogenicity of the vaccine against Omicron. This ongoing trial, which  
42 began in October 2021, was conducted at the time the Omicron variant was widely circulating.  
43 We, therefore evaluated the immune response induced by two doses of the vaccine against the  
44 Omicron (BA.1) strain in both the seropositive and seronegative subsamples at baseline.  
45 Seropositive individuals considered in this analysis were those with possible prior infection of

46 COVID-19 as indicated by a reactive anti-N protein test and pre-vaccination anti-spike antibody  
47 titers that are above the lower limit of detection.

48

## 49 **Methods**

### 50 *Study design and participants*

51 The MVC-COV1901 phase 3 trial was a parallel-group, prospective, randomized, double-  
52 blind, active-controlled, and multi-center study to evaluate the safety, tolerability, and  
53 immunogenicity of the SARS-CoV-2 vaccine candidate MVC-COV1901 compared to AZD1222  
54 in adult volunteers of 18 years and above (NCT05011526). Figure 1 outlines the trial profile and  
55 study schematic. The main study of the trial consisted of 1,030 subjects  $\geq 18$  years of age who  
56 were generally healthy or with stable pre-existing medical conditions recruited from two study  
57 sites - Asuncion and Ciudad del Este- in Paraguay. A full list of inclusion and exclusion criteria  
58 can be found in the appendix. This sample of 1,030 individuals was used for safety analysis.  
59 From this sample, the immunogenicity subset which consisted of 884 subjects, was derived. The  
60 per-protocol immunogenicity (PPI) analysis set included 225 participants.

61 The trial protocol and informed consent form were approved by the local regulatory  
62 entity (DINAVISA) and the ethics committees at the participating sites. The main institutional  
63 review board was the National University of Asuncion. The phase 3 trial was done in accordance  
64 with the principles of the Declaration of Helsinki.

### 65 *Randomization and blinding*

66 Eligible participants were unvaccinated individuals randomized to receive either MVC-  
67 COV1901 or AZD1222 in a 1:1 ratio. All participants were randomly assigned to study  
68 intervention using an interactive web response system (IWRS). Simple random sampling was  
69 used to select study participants by study site.

70 Double-blinding was employed in the study; hence, both participants and investigators  
71 were blinded to the participants' assignment of the study intervention. In case of emergency, the  
72 investigator held the sole responsibility of determining if unblinding of intervention assignment  
73 is warranted. Once Day 43 (or 14 days after the second dose) was reached, the interim analysis  
74 was carried out. Participants, investigators, site personnel, local regulators, and the sponsor staff  
75 were then unblinded to the treatment group assignments.

#### 76 *Procedures*

77 Subjects received two doses of either MVC-COV1901 or AZD1222 as scheduled in the  
78 clinical trial. Both vaccines were delivered intramuscularly at the deltoid. Serum samples were  
79 collected on the day of vaccination (Day 1) and 14 days after the second dose (Day 43 after the  
80 first dose).

81 The Medigen COVID-19 vaccine, MVC-COV1901, is a subunit vaccine consisting of the  
82 prefusion spike protein (S-2P), 750 µg CpG 1018 adjuvant and 375 µg aluminum hydroxide. A  
83 standard 0.5 mL dose contains 15 µg of the Spike-2P. The active control is AZD1222, an  
84 adenoviral vector vaccine developed by Oxford University and AstraZeneca served in multi-dose  
85 vials. Each dose of vaccine is 0.5 mL and contains  $5 \times 10^{10}$  viral particles.

86 For safety analysis, vital signs were checked before and after each injection. Individuals  
87 injected with the intervention were observed for at least 30 minutes after administration of the

88 intervention. This period is for the assessment of immediate adverse events. Participants who  
89 received at least one dose of the study intervention were evaluated for safety. Data from these  
90 were reported as part of the safety set. Participants were then asked to record any local or  
91 systemic adverse events for up to 7 days after each injection. Unsolicited adverse events were  
92 reported for 28 days after each dose of the vaccines. Other adverse events, serious adverse  
93 events, adverse events of special interest, and vaccine-associated enhanced diseases were noted  
94 throughout the study period. Levels of the severity of solicited and unsolicited adverse events  
95 were reported using modified grading scales from the US FDA Guidance for Industry [13]. The  
96 levels of severity were not noted for the reporting of “diarrhea” and “nausea” under solicited  
97 systemic AEs.

98 For immunogenicity analysis, assessments were conducted on Day 1 and Day 43.  
99 Measurement of neutralizing antibody titers was performed by central laboratories in Taiwan  
100 using validated live virus neutralization assay while determination of antigen-specific  
101 immunoglobulin (IgG) titers was performed by a laboratory in Taiwan using validated enzyme-  
102 linked immunosorbent assay (ELISA) [8]. In brief terms, the live virus neutralization assay was  
103 conducted by mixing serially-two-fold diluted sera with an equal volume of SARS-CoV-2 virus  
104 (hCoV-19/Taiwan/4/2020, GISAID accession ID: EPI\_ISL\_411927). This serum-virus mixture  
105 was incubated and added to Vero E6 cells before further incubation. Neutralizing antibody titer  
106 (NT<sub>50</sub>) was defined as the reciprocal of the highest dilution capable of inhibiting 50% of the  
107 cytopathic effect. The NT<sub>50</sub> results were calculated with the Reed-Muench method. For antigen-  
108 specific immunoglobulin titers, serum samples were analyzed in Taiwan using the ELISA  
109 method with plates coated with S-2P proteins. GMTs obtained through the assays were converted  
110 to standardized units: IU/mL for neutralizing antibody titers and BAU/mL for antigen-specific



111 immunoglobulin. For neutralizing antibodies, titers were converted using the equation:  $y =$   
112  $1.5001(x^{0.8745})$ ; where  $x$  is the value of the GMT. For the IgG titers, titers tested in Taiwan were  
113 converted to BAU/mL by multiplying by a conversion factor of 0.0912[8]. For local analysis and  
114 usage, IgG titers were also tested in a laboratory in Paraguay. Antigen-specific immunoglobulin  
115 titers were tested using the LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG assay, a chemiluminescence  
116 immunoassay (CLIA) used for the quantitative determination of anti-trimeric spike protein-  
117 specific IgG antibodies to SARS-CoV-2 in serum or plasma samples [14].

118 For the evaluation of the Omicron-neutralizing ability, neutralizing assays using  
119 pseudovirus with spike proteins of Wuhan wild-type or the Omicron variant were performed as  
120 in the previous study [12]. Twofold serial dilutions of serum samples were mixed with equal  
121 volumes of pseudovirus and incubated before adding to the HEK293-hAce2 cells. Fifty percent  
122 dilution titers (ID50) were calculated considering the uninfected cells as 100% neutralization and  
123 cells transduced with the virus as 0% neutralization.

#### 124 *Outcomes*

125 The outcomes evaluated in this study were safety, tolerability, and immunogenicity. The  
126 primary safety outcomes involved the evaluation of the safety and tolerability of MVC-  
127 COV1901 versus AZD1222. Primary safety endpoints include immediate adverse events,  
128 solicited local and systemic adverse events (evaluated up to 7 days after each dose of the study  
129 intervention), and unsolicited adverse events (assessed up to 28 days after each dose of the study  
130 intervention). The primary immunogenicity outcomes, on the other hand, were measured in wild-  
131 type anti-SARS-CoV-2 virus-neutralizing antibody GMTs, GMT ratio between MVC-COV1901  
132 and AZD1222, geometric mean fold rise (GMFR) from baseline antibody levels, and  
133 seroconversion rates (SCR) at day 14 after the second dose of the vaccine. Seroconversion is

134 defined as at least a 4-fold increase of post-intervention antibody titers from the baseline titers or  
135 half of the lower limit of detection (LoD), if undetectable, at baseline. The study aims to  
136 determine superiority in neutralizing antibodies and non-inferiority in terms of SCR of MVC-  
137 COV1901 against AZD1222 measured 14 days after the second dose of the study intervention.  
138 Superiority is established when the lower limit of the 95% confidence interval (CI) of the GMT  
139 ratio (MVC-COV1901/AZD1222) is greater than 1, while non-inferiority in SCR is considered  
140 when the lower limit of the 95% CI of the difference in SCRs (MVC-COV1901/AZD1222) is  
141 greater than or equal to -5%.

142 Secondary safety outcomes assessed included serious adverse events, adverse events of  
143 special interest, and vaccine-associated enhanced diseases, while the secondary immunogenicity  
144 outcome considered was the level of antigen-specific immunoglobulin or IgG (in BAU/mL)  
145 measured at Day 43 (i.e. 14 days after the second dose).

146 This study also investigated other dimensions of immunity induced by the primary  
147 regimen of the MVC-COV1901. The other outcomes being investigated were cross-reactive  
148 immunity against the Omicron strain of SARS-CoV-2 and non-neutralizing antibody immune  
149 effector mechanisms particularly the induction of IgG subclasses.

#### 150 *Statistical analysis*

151 The primary safety outcomes in this interim analysis were assessed in the safety set,  
152 which, as previously mentioned, included randomly assigned participants who had at least one  
153 dose of study intervention. Primary immunogenicity endpoints were evaluated using the PPI  
154 subset consisting of participants who had received two doses of the study intervention, had valid  
155 immunogenicity data on Day 43, and had no major protocol deviations up to Day 43.

156 We calculated the sample size based on the following assumptions: (1) Level of  
157 significance = 0.025 (one-sided), (2) Level of power = 0.9, (3) Expected geometric mean ratio of  
158 MVC-COV1901 to AZD1222 = 1.2 and (4) SD of natural log data = 0.81 [8]. Under the above  
159 assumptions, a sample of 417 participants per group provides a power of 90% to establish  
160 superiority of MVC-COV1901 to AZD1222 in terms of GMT ratio of neutralizing antibody titers  
161 at day 43. Furthermore, we considered a dropout rate of 11.4% resulting to a total of at least 942  
162 participants considered for the study.

163 All measured variables and derived parameters were listed by individual participant and  
164 analyzed using descriptive statistics. Summary descriptive statistics were provided for  
165 demographic/baseline characteristics, secondary immunogenicity, safety, exploratory  
166 immunogenicity, and efficacy variables. Continuous variables were summarized descriptively  
167 with the number of participants, mean, median, standard deviation (SD), interquartile range  
168 (IQR), range (minimum and maximum), and 95% CI of mean and median (when appropriate).  
169 Categorical variables were summarized with the number and percentage of participants. The  
170 geometric means of IgG and neutralizing antibody titers were calculated together with their 95%  
171 CIs, whereas GMT ratios, and their 95% CIs were obtained from the ratio of the GMTs of MVC  
172 and AZ. Significance tests (2-tailed, alpha = 0.05) without alpha adjustment were performed for  
173 pairwise comparison where appropriate and p-value was rounded to four decimal places as  
174 applicable.

175

## 176 **Results**

177 *Demographics and baseline characteristics*

178 Table 1 shows the demographic profile and baseline characteristics of the participants.  
179 We found that both groups are comparable across all baseline characteristics. There are no  
180 statistically significant differences between the two vaccine groups when considering the  
181 different demographic variables ( $p>0.05$ ). In terms of age, both groups are similar with a mean  
182 age of 32.1 years for the MVC-COV1901 group and 32.2 years for the AZD1222 group  
183 ( $p=0.8929$ ). Both groups are predominantly Latino or Hispanic and are primarily males. As in  
184 age, BMI of participants were also similar for the two groups ( $p=0.4318$ ). Lastly, there are more  
185 individuals without any comorbidity in both groups.

#### 186 *Safety outcomes*

187 The occurrence of adverse events is summarized in Figure 2 (Table S1-1 and S1-2).  
188 Overall, a total of 465 (45.1%) participants reported solicited local AEs after any dose of the  
189 study intervention: 342 (33.2%) participants after the first dose of study intervention and 239  
190 (25.8%) participants after the second dose of study intervention. The proportion of participants  
191 who reported solicited local adverse events after first and second doses of the study intervention  
192 was slightly higher in the AZD1222 group than in the MVC-COV1901 group. Majority of these  
193 participants reported Grade 1 (mild) and some reported Grade 2 (moderate) solicited local  
194 adverse events after any dose of study intervention. Pain or tenderness and injection site pruritus  
195 was the most frequently reported solicited local AE. Grade 3 adverse events were reported for  
196 pain or tenderness, injection site pruritus, and hematoma.

197 A total of 552 (53.6%) participants reported solicited systemic adverse events after any  
198 dose of the study intervention: 480 (46.6%) participants after the first dose of study intervention  
199 and 222 (24.0%) participants after the second dose of study intervention. The proportion of  
200 participants who reported solicited systemic adverse events after any dose of the study

201 intervention was slightly higher in the AZD1222 group than in the MVC-COV1901 group,  
202 specifically after the first dose of the study intervention. Most of these participants reported  
203 Grade 1 (mild) and a minority reported Grade 2 (moderate) solicited systemic adverse events.  
204 The most common solicited systemic adverse events are headache and myalgia. Grade 3 (severe)  
205 headaches were reported in the MVC-COV1901 group while a single case of Grade 4 myalgia  
206 was reported in the same group. For malaise or fatigue, 2 participants reported Grade 3 incidents  
207 after the second dose of MVC. Other reports of Grade 3 solicited systemic adverse events were  
208 made for fever, chills and joint pain.

209 A total of 16 (1.6%) participants reported unsolicited adverse events. The most frequently  
210 reported of these were gastrointestinal disorders (0.2%) and hypertension (0.2%). No unsolicited  
211 adverse events of at least Grade 3 were deemed related to study intervention. There were 3  
212 (0.3%) serious adverse events reported; 2(0.4%) of which were from the MVC-COV1901 group  
213 while 1 (0.2%) came from the AZD1222 group; however, none of these were related to the study  
214 intervention. These SAEs included celiac disease, spontaneous abortion, and COVID-19. No  
215 death, VAED, and AE leading to study withdrawal was reported at the time the interim  
216 assessment was conducted.

### 217 *Immunogenicity outcomes*

218 Figure 3 illustrates the rise in neutralizing antibody levels 14 days after the 2<sup>nd</sup> dose of the  
219 study intervention. Among the seropositive in the PPI subset the wild-type SARS-CoV-2  
220 neutralizing antibody GMT were 1905.6 IU/mL (95% CI 1617.98-2244.3) and 1143.4 IU/mL  
221 (95% CI 895.3-1460.2) for the MVC-COV1901 and AZD1222 groups, respectively. The GMFR  
222 from baseline were 26.0 (95% CI 19.5-34.7) and 15.0 times (95% CI 10.6-21.1) for MVC-  
223 COV1901 and AZD1222 groups, respectively. In the seropositive group, the GMT ratio between

224 MVC-COV1901 and AZD1222 groups was 1.7 (95% CI 1.2-2.2). For the seronegative group,  
225 GMT of the MVC-COV1901 group was 434.6 IU/mL (95% CI 333.4-566.5), while that of the  
226 AZD1222 group 90.4 IU/mL (95% CI 61.1-133.9). GMFR was higher in this subsample  
227 compared to that of the seropositive group with a value of 86.2 times (95 CI% 66.4-111.9) for  
228 the MVC and 17.9 times (95% CI 12.2-26.4) for the AZD1222 groups. The GMT ratio between  
229 groups was also higher among the seronegative with the MVC-COV1901 group having a  
230 neutralizing GMT 4.8 time (95% CI 3.0-7.7) that of the AZD1222 group.

231 Table 2 shows the seroconversion based on the wild-type SARS-CoV-2 neutralizing  
232 antibody GMTs. When considering the seronegative participants, the SCR, did not differ  
233 significantly between vaccine groups ( $p=0.218$ ). The MVC-COV1901 group had a higher SCR,  
234 with only 1 participant without seroconversion. Among the seropositive, SCRs of both groups  
235 were significantly different ( $p=0.03$ ). MVC-COV1901 had an SCR of 98.6 % (95% CI 95.9-  
236 100.0) while seroconversion was seen in 90.0% (95% CI 83.0-97.0) of the participants in the  
237 AZD1222 group.

238 Table 3 shows the IgG titers assessed in Taiwan. As previously mentioned, testing was  
239 also done in Paraguay for local analysis and usage. Results from both Taiwan and Paraguay were  
240 positively and strongly correlated (Spearman's  $r=0.80$ ,  $p<0.0001$ ). Based on data from Taiwan,  
241 the IgG GMTs in the seronegative subset of the MVC-COV1901 group increased by 239.4 times  
242 (95% CI 207.5-276.3) from baseline while that of the AZD1222 group rose by 50.8 times (95%  
243 CI 43.2-59.7). In terms of GMT ratio between MVC-COV1901 and AZD1222, results show a  
244 GMT ratio of 4.7 times (95% CI 3.8-5.9). GMFR for both groups are less when considering the  
245 seropositive subsample of the PPI subset. GMT ratio between MVC-COV1901 and AZD1222  
246 was 1.7 times (95% CI 1.5-1.99) as measured in Taiwan. Table 4 shows that the seroconversion

247 rate of antigen-specific immunoglobulin titers was 100% (95% CI 91.8-100) in the seronegative  
248 subsample of the MVC-COV1901 group on Day 43 after first dose. This was not significantly  
249 different from the seroconversion rate demonstrated by the AZD1222 group. Considering only  
250 the seropositive, MVC-COV1901 group had an SCR of 93.2% (95% CI 87.4-98.9) while the  
251 AZD1222 group had an SCR of 90.1% (95% CI 83.2-97.1).

252 Assessment of IgG subclasses reveal that the pattern of IgG response in the vaccination  
253 of both AZD1222 and MVC-COV1901 is predominantly IgG1 or IgG3 (Figure 4). High levels  
254 of IgG1 and IgG3 were induced by both vaccines, with the MVC-COV1901 inducing higher IgG  
255 subclasses than the AZD1222. Among the seronegative, IgG subclass GMT ratio of the MVC-  
256 COV1901 over AZD1222 was the highest for IgG3. Minimal IgG2 and IgG4 were produced in  
257 both groups. IgG subset levels 14 days after the second dose are shown in Figure 4. The IgG1  
258 GMTs in the seronegative is 764 BAU/mL for the MVC-COV1901 group and 208 BAU/mL for  
259 the AZD1222 group. IgG3 GMTs, on the other hand, were 608 BAU/mL and 137 BAU/mL for  
260 MVC-COV190 and AZD1222 groups, respectively. The GMT ratio between MVC-COV1901  
261 and AZD1222 for IgG1 to IgG4 among the seronegative were 3.7, 1.4, 4.4, and 1.0, respectively.

262 To test the neutralizing ability against the Omicron variant, we have subjected sera collected on  
263 Day 1 and Day 43 after the first dose (i.e. Day 14 after the second dose) to pseudovirus  
264 neutralizing assay against wildtype and the Omicron variant. As shown in Figure 5, pseudovirus  
265 neutralizing antibody titers for the wildtype was higher than that of the Omicron variant among  
266 the seropositive. The baseline reciprocal inhibition dilution 50 (ID<sub>50</sub>) GMT for the Omicron  
267 variant was slightly higher in participants in the MVC-COV1901 group (AZD1222: 13.7 [95%  
268 CI 6.4-29.4]; MVC-COV1901: 24.3 [95% CI 8.1-73.0]) but no statistical significance was seen  
269 in both vaccine groups (p=0.3661). At Day 14 after the second dose of both vaccines, ID<sub>50</sub> GMT

270 for the neutralizing antibodies against Omicron pseudovirus was 432.0 (95% CI 76.7-2433.9) for  
271 AZD1222 and 832.2 (95% CI 389.4-1778.4) for MVC-COV1901. The MVC-COV1901  
272 vaccine's level of neutralizing antibodies for the Omicron pseudovirus showed a 3.0- fold  
273 (2549.7/832.2) reduction compared to the GMT of wild-type pseudovirus and was 5.2fold  
274 (2232.6/432.0) reduction for AZD1222. Between MVC-COV1901 and AZD1222, the GMT ratio  
275 of the neutralizing antibodies for the Omicron pseudovirus at day 14 after the second dose was  
276 1.9 (95% CI 0.4-10.1). Among seronegative individuals vaccinated with MVC-COV1901, GMTs  
277 of neutralizing antibodies for the Omicron variant, were 44.5 (1323.5/29.7) times less compared  
278 to the GMTs against the wildtype pseudovirus. The GMT ratio of MVC-COV1901/AZD1222 at  
279 Day 43 for the Omicron variant was 3.0 (95% CI 1.1-8.1).

280

## 281 **Discussion**

282 In this phase III, parallel group, double-blind, randomized, active-controlled, two-arm,  
283 multi-center study, we evaluated the safety and immunogenicity of the MVC-COV1901 in adults  
284 against AZ. Initiated in October 2021, this trial met the safety and immunogenicity endpoints as  
285 stated in the protocol. Findings demonstrate the superiority of MVC-COV1901 in terms of  
286 neutralizing antibody titers and its non-inferiority in terms of resulting seroconversion rates.  
287 Neutralizing antibody GMT of MVC-COV1901 was as high as 4.8 times that of AZD1222  
288 among the seronegative individuals. Seroconversion rate, on the other hand, was 100% among  
289 seronegative. In terms of safety. MVC-COV1901 was found to be well tolerated and have fewer  
290 safety signals compared with AZD1222 and other COVID-19 vaccines [10, 15-17].



291 Safety data show that adverse events are less frequent for MVC-COV1901. Reported  
292 solicited adverse events were mostly mild or moderate. However, unlike in previous studies  
293 [8,12], adverse events that are at least Grade 3 were reported for some solicited and local adverse  
294 events such as pain or tenderness, injection site pruritus, bruising, myalgia and fever. Despite this  
295 MVC-COV1901 has a good reactogenicity profile when compared with other vaccines that  
296 received an emergency use authorization [10]. A notable finding is the lower incidence of fever  
297 in the MVC-COV1901 group (10.4%) than in the AZD1222 group (19.0%). This is however,  
298 higher compared to the ones observed in the phase 2 trial conducted in Taiwan [8]. While this  
299 differential reporting of adverse events may be due to differences in age and sex composition as  
300 well as ethnicity of both populations, it is also worth noting that there are other factors which  
301 may be of significance such as differences in other social determinants, differences in experience  
302 of receiving the vaccine, and differences in the cultural context and health systems setup [18].  
303 Unsolicited adverse events, on the other hand, were recorded on both groups. In the MVC-  
304 COV1901 group, unsolicited adverse events were reported in only 1.6% of the participants in the  
305 safety set – a rate lower compared to the reported solicited adverse events. Serious adverse  
306 events were reported by less than 1% of the participants, none of these were related to the study  
307 intervention. We suspect an underreporting of unsolicited adverse events in this clinical trial, by  
308 both participants and staff.

309 The phase 3 trial was conducted in Paraguay amidst the SARS-CoV-2 pandemic.  
310 Therefore, approximately 58% of the participants were seropositive at baseline. In the  
311 seronegative subset, the GMT of the wild-type neutralizing antibody in the MVC-COV1901  
312 group increased to approximately 86 times (95% CI 66.4-111.9) from baseline. Compared to  
313 those in the AZD1222 group, the MVC-COV1901 group had a GMT that was as high as 4.8

314 times (95% CI 3.0-7.7) in the seronegative but in the seropositive subsample GMT ratio was 1.7  
315 times (95% CI 1.2-2.2). This fulfills the superiority criterion set by the study (i.e. lower limit of  
316 the 95% CI must be greater than 1). In addition to this, seroconversion rates consistent with  
317 previous studies demonstrated favorable immunogenicity [8,12]. Most of the participants (99.1%  
318 in MVC-COV1901 group and 91.7% in AZD1222 group) in both vaccine groups achieved  
319 seroconversion based on wildtype neutralizing antibody on Day 14 after the second dose. Results  
320 show that the treatment difference between MVC-COV1901 and AZD1222 (i.e. MVC-COV1901  
321 – AZD1222) was 7.4% (95% CI: 3.8 – 10.9), fulfilling the non-inferiority criterion of MVC-  
322 COV1901 to AZD1222 in SCR of neutralizing antibody. Subgroup analysis in the seronegative  
323 subsample reveal higher GMFRs (MVC: 88.8 [95% CI 68.3-115.3]; AZ: 17.9 [95% CI 12.2-  
324 26.4]). The GMT ratio between MVC-COV1901 over AZD1222 was 4.8 times (95% CI 3.0-7.7).  
325 The difference in seroconversion rates was approximately 5.1% (95% CI: -2.1 – 12.4). These  
326 also fulfill the superiority criterion for the neutralizing antibodies and non-inferiority criterion for  
327 seroconversion.

328 In another immunobridging study, VLA-2001, an inactivated whole virus vaccine also  
329 adjuvanted with alum and CpG 1018 adjuvant, produced a GMT ratio of 1.39 between VLA-  
330 2001 and AZD1222 [19]. Both MVC-COV1901 and VLA-2001 vaccine demonstrated  
331 superiority in neutralizing antibodies according to their set criteria. Existing literature suggest  
332 that protein subunit vaccines elicit better neutralizing antibody response compared to inactivated  
333 virus vaccines [20]. Protein subunit vaccines are purified and stably locked in the preferred pre-  
334 fusion conformation thus the vaccine is presented as a correctly folded immunogen in pure form,  
335 whereas in inactivated vaccines, the purification process may affect the spike conformations  
336 [21].

337 Vaccination both by MVC-COV1901 and AZD1222 induced a Th-1 skewed immune  
338 response [12,21]. AZD1222 demonstrates a Th1-biased response characterized by antibody  
339 production predominantly of IgG1 and IgG3 subclasses [22]. In similar fashion, MVC induced a  
340 robust Th-1 biased response predominated by IgG1 and IgG3. Our results illustrate that MVC  
341 induced slightly higher IgG1 and IgG3 in the seronegative population.

342 Levels of binding and neutralizing antibodies can be correlated and used to predict  
343 vaccine efficacy [23,24]. Reported antibody titers induced by two doses of MVC-  
344 COV1901 concur with those found in previous studies [8,12] which is estimated to confer 90%  
345 vaccine efficacy against the ancestral strain [8,9]. The emergence of the other strains and  
346 particularly the Omicron strain, however, has increased ability of the virus to evade immunity,  
347 rendering two doses of currently available vaccines, largely ineffective in neutralization [25-27].  
348 In this study, we illustrate that among seronegative participants two doses of MVC-COV1901  
349 led to Omicron-neutralizing titers that are 44.5 times less than Wildtype-neutralizing titers. In the  
350 case of AZD1222, the reduction is more pronounced as neutralizing antibody titers against  
351 Omicron was barely detectable. As in most of the currently available vaccines, the primary  
352 regimen usually offers insufficient protection to the Omicron variant. Boosters are required to  
353 improve protection against it [27,28]. Results of this trial however, provide support to existing  
354 literature which suggests that natural immunity from previous infection offer a significant boost  
355 to protection offered by vaccination [29,30]. As aforementioned, SARS-CoV-2 was endemic in  
356 Paraguay at the time the study was conducted; hence, approximately 58% of the participants  
357 were seropositive. Because this trial started in October 2021 and because the first cases of  
358 Omicron were reported in December 2021 [31], the seropositive participants were probably  
359 infected by other SARS-CoV-2 variants. Data from seropositive individuals who got MVC-

360 COV1901 shots show a 3.0-fold reduction in wildtype-neutralizing titers compared to Omicron  
361 neutralizing-titers viz-a-viz the 44.5-fold reduction in the seronegative. Resulting titers among  
362 the seropositive were 1.8 times higher in MVC-COV1901-vaccinated individuals compared to  
363 those vaccinated with AZD1222. A study by Nordstrom et al. [29] suggests that two-dose hybrid  
364 immunity (i.e. immunity from two doses of the vaccine plus a previous infection) was associated  
365 with 66% lower risk of reinfection than natural immunity alone with no significant attenuation  
366 up to 9 months. Two doses of hybrid immunity was also associated with a significantly lower  
367 risk of hospitalization than natural immunity. Our results, show that among those who might  
368 have been previously infected with SARS-CoV-2, the primary regimen of MVC-COV1901  
369 induces immune response which may be sufficient against the evasive Omicron variant. In  
370 relation to existing literature, these results raise a question on issues such as the sufficiency of  
371 two doses as part of the primary vaccination regimen or the requirement of a third dose among  
372 previously infected individuals . It also highlights the idea of whether documents indicating the  
373 person's immune status should also include a history of infection.

374 We consider the following limitations of the study: first, the sample size of seronegative  
375 participants was relatively small due to high local viral transmission rate in the sites at the time  
376 of the study. However, this has added to the relevance of the study in real-world settings.  
377 Second, the short duration of follow-up did not allow for the assessment of the durability of  
378 immune responses among the seropositive and seronegative participants. Third, the  
379 neutralization assay used for the Omicron variant was a pseudovirus assay which may not  
380 accurately reflect the neutralizing ability against the Omicron (BA.1) variant.

381

382 **Declaration of Competing Interests**

383 M.-Y. L., C. E. L., J.A.E., L.E., H.-Y.C., and C.C. are employees of Medigen Vaccine  
384 Biologics Corporation. R.J. is an employee of Dynavax Technologies Corporation. J.T., O.C.T.,  
385 L.B., L.A.G., G.E., and G.S. declared no conflict of interest. All authors have reviewed and  
386 approved of the final version of the manuscript.

387 **Acknowledgements**

388 We thank the Institute of Biomedical Sciences, Academia Sinica and Protech  
389 Pharmaservices Corporation for performing the assays. For conducting the local analysis in  
390 Paraguay, we thank Les Science Lab in Coronel Oviedo, Paraguay. We also thank the members  
391 of Medigen Vaccine Biologics Corp. in assisting manuscript editing and revision.

392 **Funding statement**

393 The study was funded by Medigen Vaccine Biologics (study sponsor).

394 **Author Contribution**

395 Concept and design: C. E. L., H.-Y. C., C. C.

396 Conducting the clinical trial: J.T., O.C.T., L.B., L.A.G., G.E., G.S.

397 Acquisition, interpretation, and analysis of data: , C. E. L., M.-Y. L., H.-Y. C., J.A.E., L.E.

398 Drafting of the manuscript: C. E. L., M.-Y. L., J.A.E., L.E., R.J.

1 **Tables**

2 *Table 1. Demographic profile and baseline characteristics of participants.*

Statistic	AZD1222 N=510	MVC-COV1901 N=520	Total N=1030	p-value
<b>Age (years)</b>				
Mean (SD)	32.2 (11.70)	32.1 (12.12)	32.1 (11.91)	0.8929
Median	29.0 (16.0)	28.0 (16.0)	29.0 (16.0)	
Min, Max (Range)	18.0 ~ 71.0 (53)	18.0 ~ 91.0 (73)	18.0 ~ 91.0 (73)	
<b>Gender (n/%)</b>				
Male	315 (61.8)	304 (58.5)	619 (60.1)	0.279
Female	195 (38.2)	216 (41.5)	411 (39.9)	
<b>Ethnicity (n/%)</b>				
Latino or Hispanic	501 (98.2)	509 (97.9)	1010 (98.1)	1
White or Caucasian	8 (1.6)	9 (1.7)	17 (1.7)	
Asian	1 (0.2)	2 (0.4)	3 (0.3)	
<b>BMI (kg/m<sup>2</sup>)</b>				
Mean (SD)	27.6 (5.90)	27.3 (6.33)	27.5 (6.11)	0.432
Median	26.4 (7.7)	26.2 (7.4)	26.3 (7.6)	
Min, Max (Range)	17.0 ~ 54.7	14.9 ~ 60.1	14.9 ~ 60.1	
<b>Comorbidity</b>				
without	336 (65.9)	330 (63.5)	666(64.7)	0.416
Any	174 (34.1)	190 (36.5)	364 (35.3)	
Arrhythmia	1 (0.2)	1 (0.2)	2 (0.2)	
Arterial Hypertension	35 (6.9)	25 (4.8)	60 (5.8)	
Asthma	8 (1.6)	17 (3.3)	25 (3.4)	
Cancer	2 (0.4)	1 (0.2)	3 (0.3)	

Chronic Obstruction Pulmonary Disease (COPD)	0	4 (0.8)	4 (0.4)
Diabetes	12 (2.4)	11 (2.1)	23 (2.2)
History of drug allergy	20 (3.9)	13 (2.5)	33 (3.2)
Kidney Disease	0	4 (0.8)	4 (0.4)
Liver disease	1 (0.2)	3 (0.6)	4 (0.4)
Obesity	106 (20.8)	108 (20.8)	214 (20.8)

3

4

5 *Table 2. Seroconversion rates based on neutralizing antibody titers*

Seroconversion	AZD1222	MVC-COV1901	Treatment Difference <sup>1</sup> , %	p-value <sup>2</sup>
<b>Seropositive in PPI subset</b>				
n	70	72		0.03
Seroconversion, n(%)	63 (90)	71 (98.6)	8.6	
95% CI	82.97-97.03	95.9-100	1.1-16.1	
<b>Seronegative in PPI subset</b>				
n	39	44		0.218
Seroconversion, n(%)	37 (94.9)	44 (100.0)	5.1	
95% CI	82.7-99.4	91.95-100	-1.8-12	

6 Abbreviation: n= no. of participants, CI= confidence interval, GMT= geometric mean titer,  
7 GMFR= geometric mean fold rise, PPI=per-protocol immunogenicity

8 Note: Seroconversion was defined as at least 4-fold increase of post-study intervention antibody  
9 titers from the baseline titer or from half of the lower limit of detection if undetectable at  
10 baseline.

11 [1] Treatment Difference was computed as, MVC-COV1901-AZD1222 and presented with the  
12 asymptotic 95% CI. In the case of small cell count (expected count less than 5), exact 95% CI  
13 was applied alternatively.

14 [2] P-value: Pearson's Chi-square test. In the case of small cell count (expected count less than  
 15 5), Fisher's exact test was applied alternatively

16  
 17

18 *Table 3. Geometric Mean Titers and Geometric Mean Titer Ratio of the Antigen-Specific*  
 19 *Immunoglobulin (in BAU/mL)*

Parameter	Vaccine		GMT ratio; (95% CI)	p-value
	AZD1222	MVC-COV1901		
<b>Seropositive</b>				
n	294	264		
<i>Baseline</i>				
GMT	57.8	56.8		
95%CI	50.4-66.2	49.7-64.9		
<i>Day 14 after 2nd shot</i>				
GMT	1617.7	2812.9	1.7	<0.0001
95%CI	1460.9-1791.3	2575.4-3072.2	(1.5-1.99)	
GMFR	28.0	49.5		
95% CI	23.6-33.2	42.2-58.1		
<b>Seronegative</b>				
n	146	180		
<i>Baseline</i>				
GMT	4.6	4.6		
95%CI	4.6-4.6	4.6-4.6		
<i>Day 14 after 2nd shot</i>				
GMT	231.5	1091.8	4.7	<0.0001
95%CI	196.7-272.4	945.7-1260.5	(3.8-5.9)	
GMFR	50.8	239.4		
95% CI	43.2-59.7	207.5-276.3		

20 Abbreviation: n= no. of participants, CI= confidence interval, GMT= geometric mean titer,  
 21 GMFR= geometric mean fold rise

22 Note: [1] GMT ratio was computed as,  $GMT_{MVC-COV1901}/GMT_{AZD1222}$

23 [2] p-value based on two-sample t test or Wilcoxon rank sum test

24



25 *Table 4. Seroconversion rates based on Antigen-Specific Immunoglobulin Titers*

Statistics	AZD1222	MVC-COV1901	Treatment Difference <sup>1</sup> , %	p-value <sup>2</sup>
<b>Seropositive in PPI Subset</b>				
n	71	73		0.5135
Seroconversion, n (%)	64 (90.1)	68 (93.2)	3.0	
95% CI	(83.2-97.1)	(87.4-98.9)	(-5.9-12.0)	
<b>Seronegative in PPI Subset</b>				
n	38	43		1
Seroconversion, n (%)	38 (100.0)	43 (100.0)	0	
95% CI	(90.7-100.0)	(91.8-100.0)	(0.0-0.0)	

26 Abbreviation: n= no. of participants, CI= confidence interval, GMT= geometric mean titer,  
 27 GMFR= geometric mean fold rise, PPI=per-protocol immunogenicity


28 Note: Seroconversion was defined as at least 4-fold increase of post-study intervention antibody  
 29 titers from the baseline titer or from half of the lower limit of detection if undetectable at  
 30 baseline.

31 [1] Treatment Difference was computed as, MVC-COV1901-AZD1222 and presented with the  
 32 asymptotic 95% CI. In the case of small cell count (expected count less than 5), exact 95% CI  
 33 was applied alternatively.

34 [2] P-value: Pearson's Chi-square test. In the case of small cell count (expected count less than  
 35 5), Fisher's exact test was applied alternatively

36

## 1 Figures




2

3 *Figure 1. Trial profile*


4

A. Solicited local adverse events

First dose




Second dose




B. Solicited systemic adverse events

First dose



Second dose




5

6 *Figure 2. Solicited local (A) and systemic (B) adverse events occurring within 7 days of the first*  
 7 *and second doses of MVC-COV1901 or AZD1222. Adverse events were graded as mild*  
 8 *(grade 1), moderate (grade 2), severe (grade 3), or disabling (grade 4)*

9


10



12 *Figure 3. Neutralizing antibody titer in subjects immunized with two doses of either AZD1222 or*  
13 *MVC-COV1901 among the seropositive subsample (left) and seronegative subset.*

14 *Serum samples were taken before the first vaccination (V2) and 14 days (V4) after the second*  
15 *dose of the study intervention and were analyzed using live SARS-CoV-2 neutralization assay.*  
16 *The results are shown as IU/mL with symbols indicating individual IU values and the bars*  
17 *indicating the GMT of each group.*

19




GMT Ratios (MVC-COV1901/AZD1222): IgG1=3.7; IgG2=1.4; IgG3=4.4; IgG4=1.0

20

21 *Figure 14. IgG subclass titers for the seronegative subsample. Depicted are geometric mean*  
 22 *titers with 95% confidence intervals for the four subclasses of IgG.*

23



GMT Ratio, MVC\_COV1901/AZD1222 (Omicron): 1.93

GMT Ratio, MVC\_COV1901/AZD1222 (Omicron): 2.97

24

25 *Figure 5. Results of pseudovirus neutralizing assay against wildtype and the Omicron variant.*  
 26 *Serum samples taken on Day 43 after the first dose (14 days after the second dose) from 16*  
 27 *seropositive and 14 seronegative participants who were randomly selected. The results were*  
 28 *presented by horizontal bars representing geometric mean titer with error bars for 95%*  
 29 *confidence interval values.*

30

## 1 REFERENCES

- 2 1. Our world in data. Statistics and research coronavirus pandemic (COVID-19) [cited 2022  
3 April 20]. Available from: <https://ourworldindata.org/coronavirus>.
- 4 2. Harvey, W.T., Carabelli, A.M., Jackson, B. et al. SARS-CoV-2 variants, spike mutations  
5 and immune escape. *Nat Rev Microbiol* 19, 409–424 (2021).  
6 <https://doi.org/10.1038/s41579-021-00573-0>
- 7 3. Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, Sukhova K, Kaforou  
8 M, Bailey D, Barclay WS. The SARS-CoV-2 variant, Omicron, shows rapid replication in  
9 human primary nasal epithelial cultures and efficiently uses the endosomal route of entry.  
10 *BioRxiv*. 2022 Jan 1:2021-12.
- 11 4. Planas D, Saunders N, Maes P, Benhassine FG, Planchais C, Porrot F, Staropoli I,  
12 Lemoine F, Pere H, Veyer D, Puech J. Considerable escape of SARS-CoV-2 variant  
13 Omicron to antibody neutralization. *bioRxiv*. 2021 Jan 1.
- 14 5. Iketani S, Liu L, Guo Y, Liu L, Huang Y, Wang M, Luo Y, Yu J, Yin MT, Sobieszczyk  
15 ME, Huang Y. Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages.  
16 *bioRxiv*. 2022 Jan 1.
- 17 6. Kuo TY, Lin MY, Coffman RL, Campbell JD, Traquina P, Lin YJ, Liu LT, Cheng J, Wu  
18 YC, Wu CC, Tang WH. Development of CpG-adjuvanted stable prefusion SARS-CoV-2  
19 spike antigen as a subunit vaccine against COVID-19. *Scientific reports*. 2020 Nov  
20 18;10(1):1-0.
- 21 7. COVID 19 Vaccine Tracker [cited 2022 April 20]. Available from:  
22 <https://covid19.trackvaccines.org/>.


- 23 8. Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP,  
24 Wang NC, Lee YL, Lin YL. Safety and immunogenicity of CpG 1018 and aluminium  
25 hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim  
26 results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in  
27 Taiwan. *The Lancet Respiratory Medicine*. 2021 Dec 1;9(12):1396-406.
- 28 9. Estrada, Josue A., Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-  
29 Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, Robert Janssen, and I-Feng Lin. 2022.  
30 "An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults  
31 Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-  
32 COV1901" *Vaccines*. 2022. 10, no. 5: 655. <https://doi.org/10.3390/vaccines10050655>
- 33 10. Taiwan Centers for Disease Control. V-Watch Bulletin Report 2022 March, 2021 [cited  
34 2022 April 20]. Available from:  
35 [https://www.cdc.gov.tw/File/Get/Xwv8akaYldqmvISsN3\\_H5Q](https://www.cdc.gov.tw/File/Get/Xwv8akaYldqmvISsN3_H5Q).
- 36 11. Liu, LTC, Chiu, CH, Chiu NC, Tan BF, Lin CY, Lin MY, Lien CE, Chen C, Huang LM.  
37 Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in  
38 Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial. *medRxiv*. 2022 Mar  
39 15.
- 40 12. Hsieh S-M, Liu W-D, Huang Y-S, Lin Y-J, Hsieh E-F, Lian W-C, et al. Safety and  
41 immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein  
42 Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in  
43 healthy adults: A Phase 1, dose-escalation study. *eClinicalMedicine*. 2021;38.
- 44 13. U.S. Food and Drug Administration. Guidance for industry: toxicity grading scale for  
45 healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.

- 46 September 2007. Rockville, MD: Center for Biologics Evaluation and Research. 2007  
47 [cited May 2022] Available from [https://www.fda.gov/regulatory-information/search-fda-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)  
48 [guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)  
49 [enrolled-preventive-vaccine-clinical](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical).
- 50 14. LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG assay, A quantitative assay for immune status  
51 monitoring with an accurate correlation of neutralizing IgG antibodies: Product manual.  
52 [cited June 2022] Available from [https://www.diasorin.com/en/immunodiagnostic-](https://www.diasorin.com/en/immunodiagnostic-solutions/clinical-areas/infectious-diseases/covid-19)  
53 [solutions/clinical-areas/infectious-diseases/covid-19](https://www.diasorin.com/en/immunodiagnostic-solutions/clinical-areas/infectious-diseases/covid-19)
- 54 15. Fan, Yu-Jing, Kwok-Hung Chan, and Ivan F.-N. Hung. 2021. "Safety and Efficacy of  
55 COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at  
56 Phase 3. *Vaccines*. 2021, 9(9): 989.
- 57 16. Rosenblum HG, Gee J, Liu R, Marquez PL, Zhang B, Strid P, et al. Safety of mRNA  
58 vaccines administered during the initial 6 months of the US COVID-19 vaccination  
59 programme: an observational study of reports to the Vaccine Adverse Event Reporting  
60 System and v-safe. *The Lancet Infectious Diseases*. 2022, 22(6); 802 – 812
- 61 17. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et  
62 al. Safety of COVID-19 vaccines. *J Med Virol*. 2021;93(12):6588–94
- 63 18. Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and  
64 Adverse Effects Following Vaccination. *JAMA Netw Open*. 2021; 4(12) :e2140364
- 65 19. Valneva. Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-  
66 19 Vaccine Candidate VLA2001: Press Release. 2021 [cited May 2022] Retrieved from  
67 [https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-](https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/)  
68 [inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/](https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/)




- 69 20. McDonald, I., Murray, S.M., Reynolds, C.J. et al. Comparative systematic review and  
70 meta-analysis of reac-togenicity, immunogenicity and efficacy of vaccines against SARS-  
71 CoV-2. *npj Vaccines* 6, 74 (2021). <https://doi.org/10.1038/s41541-021-00336-1>
- 72 21. Heinz, F.X., Stiasny, K. Distinguishing features of current COVID-19 vaccines: knowns  
73 and unknowns of antigen presentation and modes of action. *npj Vaccines* 6, 104 (2021).  
74 <https://doi.org/10.1038/s41541-021-00369-6>
- 75 22. Ewer, K.J., Barrett, J.R., Belij-Rammerstorfer, S. et al. T cell and antibody responses  
76 induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2  
77 clinical trial. *Nat Med* 27, 270–278 (2021). <https://doi.org/10.1038/s41591-020-01194-5>
- 78 23. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, et al. Immune  
79 Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv.  
80 2021.
- 81 24. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection  
82 against symptomatic and asymptomatic SARS-CoV-2 infection. *Nature Medicine*.  
83 2021;27(11):2032-40.
- 84 25. Pérez-Then, E., Lucas, C., Monteiro, V.S. et al. Neutralizing antibodies against the  
85 SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus  
86 BNT162b2 booster vaccination. *Nat Med*. 2022. 28, 481–485.
- 87 26. Gruell, H., Vanshylla, K., Tober-Lau, P. et al. mRNA booster immunization elicits potent  
88 neutralizing serum activity against the SARS-CoV-2 Omicron variant. *Nat Med*.2022. 28,  
89 477–480

- 90 27. Singanallur NB, van Vuren PJ, McAuley AJ, Bruce MP, Kuiper MJ, et al. At Least Three  
91 Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron  
92 Variant. *Front Immunol.* 2022. 13:883612
- 93 28. Shen, X. Boosting immunity to Omicron. *Nat Med.* 2022. 28, 445–446  
94 <https://doi.org/10.1038/s41591-022-01727-0>
- 95 29. Nordström, Peter et al. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation  
96 in individuals with natural and hybrid immunity: a retrospective, total population cohort  
97 study in Sweden. *The Lancet Infectious Diseases.* 2022. 22(6); 781 - 790
- 98 30. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al.  
99 Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *N*  
100 *Engl J Med.* 2022. 386: 1532-1546
- 101 31. Reuters. Paraguay confirms first cases of Omicron variant of coronavirus. 28 December  
102 2021. [cited June 2022] Retrieved from  
103 [https://www.reuters.com/world/americas/paraguay-confirms-first-cases-omicron-variant-](https://www.reuters.com/world/americas/paraguay-confirms-first-cases-omicron-variant-coronavirus-2021-12-27/)  
104 [coronavirus-2021-12-27/](https://www.reuters.com/world/americas/paraguay-confirms-first-cases-omicron-variant-coronavirus-2021-12-27/)




## A. Solicited local adverse events

### First dose




### Second dose




## B. Solicited systemic adverse events


### First dose



### Second dose




### Seropositive only




GMT Ratio, MVC-COV1901/AZD1222: 1.7

### Seronegative only




GMT Ratio, MVC-COV1901/AZD1222 : 4.8




GMT Ratios (MVC-COV1901/AZD1222): IgG1=3.7; IgG2=1.4; IgG3=4.4; IgG4=1.0

### Seropositive only



GMT Ratio, MVC\_COV1901/AZD1222 (Omicron): 1.93

### Seronegative only



GMT Ratio, MVC\_COV1901/AZD1222 (Omicron): 2.97